Men's Weekly

.

Business Telegraph

.

Marketing application of BOGUTAI® (teriparatide injection) has been officially accepted by the China National Medical Products Administration (NMPA)

  • Written by Telegraph Magazine

HONG KONG SAR - EQS Newswire - 29 June 2022 - A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (the "Company", together with its subsidiaries, the "Group"; Stock code: 00690.HK) is pleased to announce that t the marketing application submitted by the Group's self-developed BOGUTAI® (teriparatide injection) has been accepted by the China National Medical Products Administration ("NMPA") on 28 June 2022, with the acceptance number "CXSS2200062国".

If BOGUTAI® is approved for marketing, it will provide patients with better drug choices, which is a major milestone for the company in the field of orthopedic diseases.

BOGUTAI® (teriparatide injection) is the Group's fifth marketed product following GENETIME® , GENESOFT® , PINUP® , BOKANGTAI®, and it is also the first domestic manufactured PTH Liquid in China to use a disposable injection pen. Developed in collaboration with Swiss self-care giant Ypsomed, this product has an extremely thin injection needle and high dose accuracy, which can greatly reduce the pain of injections for patients. The Group strongly believe BOGUTAI® will be a future blockbuster for the Group by virtue of the product's strong cost advantage, better therapeutic effect and convenient administration method.

Teriparatide injection adopts biological expression technology, and is a recombinant human parathyroid hormone analog (PTH1-34), which has the same sequence as the 34-amino acid N-terminal amino acid (biologically active region) of human parathyroid hormone of 84 amino acids. For the treatment of osteoporosis in postmenopausal women with a high risk of fractures, it is the only osteogenesis-promoting anti-osteoporosis drug approved for marketing at home and abroad, which can effectively improve bone microstructure, increase bone strength, promote bone healing, and significantly reduce the risk of vertebral and nonvertebral fractures in postmenopausal women.

China is the country with the largest number of osteoporosis in the world. According to the data of the seventh census in 2021, there are currently 264.02 million people aged 60 and above in my country, accounting for 18.70%. Epidemiological surveys show that the prevalence of osteoporosis among people over 50 years old in China is 20.7% for women and 14.4% for men; the prevalence of osteoporosis among people over 60 years old is significantly higher, and women are particularly prominent, as high as 51.6%. Hence, there are currently about 90 million osteoporosis patients in China, and the osteoporosis market size is about 15 billion to 20 billion yuan. The current market share of teriparatide is only about 1% of the PRC osteoporosis market, which is significantly lower than that of foreign countries. The main reason is that it is expensive and not covered by medical insurance. However, in the long run, with the aging of Chinese's population, the gradual improvement of the coverage of the medical insurance system and the improvement of residents' purchasing power, the market size of teriparatide will accelerate significant. Moreover, BOGUTAI's product positioning of being more cost-effective and safe fits the needs of target demographic better, ensuring faster growth compared to other teriparatide competitors.

About Uni-Bio Science Group

Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of biopharmaceutical products. The research and development center is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group has two GMP manufacturing bases in Beijing and Shenzhen. The Group also has a highly efficient commercialization platform and marketing network. The Group focuses on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine as diabetes and osteoporosis, ophthalmology and dermatology. Please visit the official website of Uni-Bio Science Group for more information:

#UniBioScienceGroup

Entrepreneurs & Leaders

Wang Chuanfu Attends BYD Harmony’s 100th Overseas Store Opening

                                                                 Dignitaries inaugurate the new storeOn July 12, 2025, M...

A Step-by-Step Guide on How to Open Company in Poland

Poland continues to be a highly attractive destination for global entrepreneurs seeking new opportunities within the E...

What Sets a Top Commercial Plasterer Contractor Apart in Melbourne’s Competitive Market

Melbourne’s commercial construction scene moves fast. Whether it is a retail space on Chapel Street, a high-rise offic...

Justice for Workplace Injuries: How to Find the Best Compensation Lawyer

Finding an experienced compensation attorney who focuses on workplace injury claims is one of the most crucial actions...

Overcoming Internal Resistance to Adopting Headless CMS

Like any technological shift in an organization, there is always internal resistance to be mitigated. Transitioning to...

Understanding Australian Electrical Compliance: Key to Workplace Safety

In Australia, workplace safety is a priority, particularly when dealing with electrical systems. Adherence to Australi...

How Mobile Mechanics in Sydney Are Transforming the Lives of Busy Professionals

In a fast-paced city like Sydney, where every hour counts, finding time for car maintenance can be a challenge. For bu...

Beyond the Marker: How Modern Whiteboards Drive Team Collaboration

Collaboration in the workplace has undergone a transformation. With the rise of hybrid work models, agile project mana...

Essential Strata Insurance Services Every Multi-Owner Building Must Get Right

When multiple parties share ownership in a property, ensuring its longevity and protection demands more than just good...